ConductScience.org, home

Library / Trials

Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens

NCT07932002, Phase 4, Recruiting, IMMUNOe Research Centers

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleExploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious PathogensClinicalTrials.gov
NCT numberNCT07932002ClinicalTrials.gov
StatusRecruitingClinicalTrials.gov
PhasesPhase 4ClinicalTrials.gov
Enrollment30 participants, estimatedClinicalTrials.gov
Lead sponsorIMMUNOe Research CentersClinicalTrials.gov
ConditionsPost SARS-CoV2 (COVID-19), Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), COVID - 19ClinicalTrials.gov
InterventionsRuconestClinicalTrials.gov
First posted2026-11-12ClinicalTrials.gov
Last updated2026-11-12ClinicalTrials.gov

Registered outcomes 84

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryNeuropsychological Measures (BRIEF-A)Week 0Behavior Rating Inventory of Executive Function - AdultClinicalTrials.gov
PrimaryNeuropsychological Measures (BRIEF-A)Week 5Behavior Rating Inventory of Executive Function - AdultClinicalTrials.gov
PrimaryNeuropsychological Measures (BRIEF-A)Week 9Behavior Rating Inventory of Executive Function - AdultClinicalTrials.gov
PrimaryNeuropsychological Measures (BRIEF-A)Week 13Behavior Rating Inventory of Executive Function - AdultClinicalTrials.gov
PrimaryNeuropsychological Measures (BRIEF-A)Week 17Behavior Rating Inventory of Executive Function - AdultClinicalTrials.gov
PrimaryNeuropsychological Measures (BRIEF-A)Week 21Behavior Rating Inventory of Executive Function - AdultClinicalTrials.gov
PrimaryNeuropsychological Measures (BRIEF-A)Week 25Behavior Rating Inventory of Executive Function - AdultClinicalTrials.gov
PrimaryNeuropsychological Measures (RBANS)Week 0Repeatable Battery for the Assessment of Neuropsychological StatusClinicalTrials.gov
PrimaryNeuropsychological Measures (RBANS)Week 5Repeatable Battery for the Assessment of Neuropsychological StatusClinicalTrials.gov
PrimaryNeuropsychological Measures (RBANS)Week 9Repeatable Battery for the Assessment of Neuropsychological StatusClinicalTrials.gov
PrimaryNeuropsychological Measures (RBANS)Week 13Repeatable Battery for the Assessment of Neuropsychological StatusClinicalTrials.gov
PrimaryNeuropsychological Measures (RBANS)Week 17Repeatable Battery for the Assessment of Neuropsychological StatusClinicalTrials.gov
PrimaryNeuropsychological Measures (RBANS)Week 21Repeatable Battery for the Assessment of Neuropsychological StatusClinicalTrials.gov
PrimaryNeuropsychological Measures (RBANS)Week 25Repeatable Battery for the Assessment of Neuropsychological StatusClinicalTrials.gov
PrimaryNeuropsychological Measures (BDI II)Week 0Beck Depression Inventory (BDI II)ClinicalTrials.gov
PrimaryNeuropsychological Measures (BDI II)Week 5Beck Depression Inventory (BDI II)ClinicalTrials.gov
PrimaryNeuropsychological Measures (BDI II)Week 9Beck Depression Inventory (BDI II)ClinicalTrials.gov
PrimaryNeuropsychological Measures (BDI II)Week 13Beck Depression Inventory (BDI II)ClinicalTrials.gov
PrimaryNeuropsychological Measures (BDI II)Week 17Beck Depression Inventory (BDI II)ClinicalTrials.gov
PrimaryNeuropsychological Measures (BDI II)Week 21Beck Depression Inventory (BDI II)ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)